Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 51, 2021 - Issue 3
Submit an article Journal homepage
166
Views
3
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects

Yuqing Zhaoa Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Lijun Xiea Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Ning Oua Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Jie Wub Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, ChinaView further author information
,
Hongwen Zhanga Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Sufeng Zhoua Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Yun Liua Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Juan Chena Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Lu Wanga Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Libin Wanga Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaView further author information
,
Jingjing Wangb Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, ChinaView further author information
&
Feng Shaoa Phase I Clinical Trial Unit, Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University, Nanjing, China;c Pharmacy College, Nanjing Medical University, Nanjing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 297-306 | Received 19 Oct 2020, Accepted 11 Dec 2020, Published online: 28 Dec 2020

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.